GDRX250117C2500
- 1.95
- 0.000.00%
GoodRx Newsroom
55% Of This GoodRx Holdings Insider's Holdings Were Sold
Raymond James Adds UnitedHealth to Analyst Current Favorites List, Cuts GoodRx
Mizuho Securities Maintains GoodRx(GDRX.US) With Hold Rating
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
GoodRx Holdings: Navigating Leadership Transition and Legislative Uncertainty
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $6
GoodRx Holdings Analyst Ratings
Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Cuts Target Price to $6
GoodRx Price Target Lowered to $6 From $7 at Morgan Stanley
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
GoodRx Stock Rises 5% After New CEO Appointment
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $9
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $4.5
Sell Rating Maintained for GoodRx Holdings Amid Volatility and Strategic Challenges
Positive Outlook for GoodRx Holdings Under New Leadership: Buy Rating and 52.5% Potential Return
GoodRx Names Wendy Barnes as CEO